<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137916</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571BDE70</org_study_id>
    <nct_id>NCT01137916</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Imatinib in Desmoid Tumors</brief_title>
  <official_title>Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to evaluate the activity and safety of imatinib in
      patients with aggressive fibromatosis who, after receiving the standard therapy, show an
      inoperable recurrent tumor or disease not readily controllable by surgery or radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-progression rate after 6 months of treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-progression rate after 12 and 24 months of treatment</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) and overall survival (OS)</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording of patient quality of life</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Aggressive Fibromatosis</condition>
  <condition>Desmoid Tumor</condition>
  <arm_group>
    <arm_group_label>drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib 800 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>800 mg</description>
    <arm_group_label>drug</arm_group_label>
    <other_name>Glivec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histological confirmed aggressive fibromatosis (desmoid tumor)

          -  Measurable disease according to the RECIST criteria

          -  Evidence of relapse or disease progression within the last 6 months (based on RECIST
             criteria) in computed tomography or magnetic resonance imaging

          -  No possibility of complete surgical resection or cases in which surgical therapy
             leaving a large tissue defect, functional deficit or disfigurement would be required

          -  No possibility of curative radiotherapy with acceptable toxicity and/or late morbidity

          -  Previous treatment of the tumor region by surgical intervention and/or radiotherapy
             and/or antihormonal therapy possible

          -  Age &gt; or = 18 years

          -  WHO PS &lt; or = 1

          -  Effective contraception during study medication

          -  Signed informed consent form

        Exclusion Criteria:

          -  Surgical intervention &lt; 4 weeks

          -  Prior therapy with imatinib

          -  Pregnancy or lactation

          -  Severe hepatic dysfunction

          -  Known allergic reaction to imatinib or one of its components

          -  The following laboratory values: Absolute neutrophil count &lt; 1.5 x 103/mm3, Platelets
             &lt; 100,000/mm3, Serum creatinine &gt; or = 2.5 mg/dl, SGOT and/or SGPT &gt; 2.5 x ULN (upper
             limit of normal), Total bilirubin &gt; 1.5 x ULN

          -  Participation in another study (four weeks before and during the study)

          -  Prior malignancy apart from completely resected basal cell carcinoma of the skin or
             carcinoma in situ of the uterine cervix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Kasper, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Heidelberg, Mannheim University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Heidelberg, Mannheim University Medical Center</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.gisg.de</url>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Bernd Kasper</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
    <mesh_term>Fibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

